Evidence map›Paper›PMID 37224326›Full record

ArticleF1000Research2022

Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya.

Zakayo Mwangi, Grace Naeku, Marianne Mureithi, Frank Onyambu, Wallace Bulimo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in F1000Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Macrolide resistance inJAC-antimicrobial resistance · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Zakayo MwangiDepartment of Medical Microbiology and Immunology, University of Nairobi, Nairobi, Nairobi, 30197, Kenya.
Grace NaekuMolecular and Infectious Disease Research Laboratory, University of Nairobi, Nairobi, Nairobi, 30197, Kenya.
Marianne MureithiDepartment of Medical Microbiology and Immunology, University of Nairobi, Nairobi, Nairobi, 30197, Kenya.
Frank OnyambuDepartment of Medical Laboratory Science, Meru University of Science and Technology, Meru, Meru, 972, Kenya.ORCID 0000-0002-1195-8762
Wallace BulimoKenya Medical Research Institute, Kenya Medical Research Institute, Nairobi, Nairobi, 54840, Kenya.ORCID 0000-0001-8475-0586
University of Nairobi · KEKenya Medical Research Institute · KEMeru University of Science and Technology · KE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-tuberculous mycobacteria (NTM) treatment constitutes a macrolide-based antibiotic regimen in combination with aminoglycosides for Rapid-Growing Mycobacteria (RGM), and rifampicin for Slow-Growing Mycobacteria (SGM). Mutations in the anti-NTM drug target regions promote NTM evolution to mutant strains that are insusceptible to NTM drugs leading to treatment failure. We, therefore, described the mutation patterns of anti-NTM drug target genes including

resultsNTM harboring mutations associated with resistance to at least one of the antibiotics used in the macrolide-based therapy were 23% (28/122). Of these NTM, 10.4% (12/122) had mutations in the

conclusionWe demonstrated a significant level of mutations associated with drug resistance for macrolides, aminoglycosides, and rifampicin in NTM isolated from symptomatic TB negative patients in Kenya.

Indexed as

AminoglycosidesRifampinAnti-Bacterial AgentsCross-Sectional StudiesHumansKenyaMacrolidesMutationNontuberculous MycobacteriaAminoglycosidesAnti-Bacterial AgentsMacrolidesRifampinaminoglycosidesmacrolidesNontuberculous mycobacteriarapid-growing mycobacteriarifampicinslow-growing mycobacteria

Identifiers

PMID37224326
PMCPMC10186554
OpenAlexW4362589630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.